Currently, there is already experience with inhibitory drugs for the JAK receptor family; thus, tofacitinib for JAK1, JAK2, JAK3, and Tyk2; and baricitinib, which selectively act on JAK1 and JAK2 and are used in RA therapy [116,117]. This evidence concerns the gene JAK2 and rheumatoid arthritis.